Published in Proc Natl Acad Sci U S A on April 01, 2010
Structural basis of substrate discrimination and integrin binding by autotaxin. Nat Struct Mol Biol (2011) 1.81
Autotaxin expression from synovial fibroblasts is essential for the pathogenesis of modeled arthritis. J Exp Med (2012) 1.76
Insights into autotaxin: how to produce and present a lipid mediator. Nat Rev Mol Cell Biol (2011) 1.37
Regulation of mammalian physiology, development, and disease by the sphingosine 1-phosphate and lysophosphatidic acid receptors. Chem Rev (2011) 1.29
Autotaxin and its product lysophosphatidic acid suppress brown adipose differentiation and promote diet-induced obesity in mice. Mol Endocrinol (2012) 1.21
Chemical evolution of autotaxin inhibitors. Chem Rev (2012) 1.12
Binding of autotaxin to integrins localizes lysophosphatidic acid production to platelets and mammalian cells. J Biol Chem (2011) 1.11
Autotaxin through lysophosphatidic acid stimulates polarization, motility, and transendothelial migration of naive T cells. J Immunol (2012) 1.10
Mechanism of rapid elimination of lysophosphatidic acid and related lipids from the circulation of mice. J Lipid Res (2013) 1.09
Role of the autotaxin-lysophosphatidate axis in cancer resistance to chemotherapy and radiotherapy. Biochim Biophys Acta (2012) 1.04
The autotaxin-LPA axis emerges as a novel regulator of lymphocyte homing and inflammation. J Immunol (2014) 1.04
Lysophosphatidic acid in atherosclerotic diseases. Br J Pharmacol (2012) 1.01
Controlling cancer through the autotaxin-lysophosphatidic acid receptor axis. Biochem Soc Trans (2012) 1.01
Sphingosine kinase type 1 inhibition reveals rapid turnover of circulating sphingosine 1-phosphate. Biochem J (2011) 0.99
Benzyl and naphthalene methylphosphonic acid inhibitors of autotaxin with anti-invasive and anti-metastatic activity. ChemMedChem (2011) 0.95
Arguing the case for the autotaxin-lysophosphatidic acid-lipid phosphate phosphatase 3-signaling nexus in the development and complications of atherosclerosis. Arterioscler Thromb Vasc Biol (2014) 0.94
The phospholipase A1 activity of lysophospholipase A-I links platelet activation to LPA production during blood coagulation. J Lipid Res (2011) 0.93
Kinetic analysis of autotaxin reveals substrate-specific catalytic pathways and a mechanism for lysophosphatidic acid distribution. J Biol Chem (2011) 0.91
Mammalian cell expression, purification, crystallization and microcrystal data collection of autotaxin/ENPP2, a secreted mammalian glycoprotein. Acta Crystallogr Sect F Struct Biol Cryst Commun (2010) 0.90
A novel highly potent autotaxin/ENPP2 inhibitor produces prolonged decreases in plasma lysophosphatidic acid formation in vivo and regulates urethral tension. PLoS One (2014) 0.90
Chemical modulation of glycerolipid signaling and metabolic pathways. Biochim Biophys Acta (2014) 0.89
Target highlights in CASP9: Experimental target structures for the critical assessment of techniques for protein structure prediction. Proteins (2011) 0.89
Aromatic phosphonates inhibit the lysophospholipase D activity of autotaxin. Bioorg Med Chem Lett (2011) 0.89
Expression of LPP3 in Bergmann glia is required for proper cerebellar sphingosine-1-phosphate metabolism/signaling and development. Glia (2011) 0.88
Lysophosphatidic acid inhibits CD8 T cell activation and control of tumor progression. Cancer Immunol Res (2013) 0.87
Structure-based design of novel boronic acid-based inhibitors of autotaxin. J Med Chem (2011) 0.87
The effects of aspirin and fish oil consumption on lysophosphatidylcholines and lysophosphatidic acids and their correlates with platelet aggregation in adults with diabetes mellitus. Prostaglandins Leukot Essent Fatty Acids (2013) 0.86
Lysophosphatidate induces chemo-resistance by releasing breast cancer cells from taxol-induced mitotic arrest. PLoS One (2011) 0.85
Lack of lipid phosphate phosphatase-3 in embryonic stem cells compromises neuronal differentiation and neurite outgrowth. Dev Dyn (2012) 0.85
Regulation of autotaxin expression and secretion by lysophosphatidate and sphingosine 1-phosphate. J Lipid Res (2015) 0.84
A metabolically-stabilized phosphonate analog of lysophosphatidic acid attenuates collagen-induced arthritis. PLoS One (2013) 0.84
Molecular cause and functional impact of altered synaptic lipid signaling due to a prg-1 gene SNP. EMBO Mol Med (2015) 0.84
Synthesis and structure-activity relationships of tyrosine-based inhibitors of autotaxin (ATX). Bioorg Med Chem Lett (2010) 0.83
Integrin-mediated cell surface recruitment of autotaxin promotes persistent directional cell migration. FASEB J (2013) 0.83
Hits of a high-throughput screen identify the hydrophobic pocket of autotaxin/lysophospholipase D as an inhibitory surface. Mol Pharmacol (2013) 0.82
Boron chemicals in diagnosis and therapeutics. Future Med Chem (2013) 0.82
Mitigation of the hematopoietic and gastrointestinal acute radiation syndrome by octadecenyl thiophosphate, a small molecule mimic of lysophosphatidic acid. Radiat Res (2015) 0.82
Exocrine pancreatic carcinogenesis and autotaxin expression. PLoS One (2012) 0.81
Requirement of Osteopontin in the migration and protection against Taxol-induced apoptosis via the ATX-LPA axis in SGC7901 cells. BMC Cell Biol (2011) 0.81
Docosatetraenoyl LPA is elevated in exhaled breath condensate in idiopathic pulmonary fibrosis. BMC Pulm Med (2014) 0.81
Insulin-like growth factor 1 (IGF-1) stabilizes nascent blood vessels. J Biol Chem (2015) 0.81
Autotaxin, a lysophospholipase D with pleomorphic effects in oncogenesis and cancer progression. J Lipid Res (2015) 0.80
Autotaxin: its role in biology of melanoma cells and as a pharmacological target. Enzyme Res (2011) 0.79
Ligand-based autotaxin pharmacophore models reflect structure-based docking results. J Mol Graph Model (2011) 0.79
Bioactive lysophospholipids: role in regulation of aqueous humor outflow and intraocular pressure in the context of pathobiology and therapy of glaucoma. J Ocul Pharmacol Ther (2013) 0.78
Steroid binding to Autotaxin links bile salts and lysophosphatidic acid signalling. Nat Commun (2016) 0.78
The polybasic insertion in autotaxin α confers specific binding to heparin and cell surface heparan sulfate proteoglycans. J Biol Chem (2012) 0.78
The Autotaxin-Lysophosphatidic Acid Axis Modulates Histone Acetylation and Gene Expression during Oligodendrocyte Differentiation. J Neurosci (2015) 0.78
Non-invasive imaging of tumors by monitoring autotaxin activity using an enzyme-activated near-infrared fluorogenic substrate. PLoS One (2013) 0.78
Autotaxin inhibitors: a perspective on initial medicinal chemistry efforts. Expert Opin Ther Pat (2010) 0.77
Dendrimer Conjugate of [4-(Tetradecanoylamino)benzyl]phosphonic Acid (S32826) as an Autotaxin Inhibitor. ACS Med Chem Lett (2013) 0.76
Lysophospholipid mediators in the vasculature. Exp Cell Res (2015) 0.76
Possible role of lysophosphatidic acid in rat model of hypoxic pulmonary vascular remodeling. Pulm Circ (2014) 0.76
Distinct functional and conformational states of the human lymphoid tyrosine phosphatase catalytic domain can be targeted by choice of the inhibitor chemotype. J Comput Aided Mol Des (2011) 0.76
Repurposing Suzuki coupling reagents as a directed fragment library targeting serine hydrolases and related enzymes. J Med Chem (2017) 0.75
Vinyl sulfone analogs of lysophosphatidylcholine irreversibly inhibit autotaxin and prevent angiogenesis in melanoma. Bioorg Med Chem (2015) 0.75
Integrating chemical and genetic silencing strategies to identify host kinase-phosphatase inhibitor networks that control bacterial infection. ACS Chem Biol (2013) 0.75
Novel Autotaxin Inhibitors for the Treatment of Osteoarthritis Pain: Lead Optimization via Structure-Based Drug Design. ACS Med Chem Lett (2016) 0.75
c-Jun promotes cell migration and drives expression of the motility factor ENPP2 in soft tissue sarcomas. J Pathol (2014) 0.75
Lysophosphatidic acid-induced itch is mediated by signalling of LPA5 receptor, phospholipase D and TRPA1/TRPV1. J Physiol (2017) 0.75
Autotaxin-mediated lipid signaling intersects with LIF and BMP signaling to promote the naive pluripotency transcription factor program. Proc Natl Acad Sci U S A (2016) 0.75
The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer (2003) 6.70
Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol (2002) 5.52
The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat Med (2007) 5.06
The ins and outs of lysophosphatidic acid signaling. Bioessays (2004) 3.62
Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase. J Biol Chem (2002) 3.53
Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell (2009) 3.36
Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Lett (1998) 3.32
Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Mol Cell Biol (2006) 3.24
Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein. J Biol Chem (1992) 2.93
Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid. J Biol Chem (2006) 2.79
Autotaxin, an ectoenzyme that produces lysophosphatidic acid, promotes the entry of lymphocytes into secondary lymphoid organs. Nat Immunol (2008) 2.64
Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome. Structure (2006) 2.56
Regulation and biological activities of the autotaxin-LPA axis. Prog Lipid Res (2007) 2.39
Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J Clin Invest (2004) 2.30
Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. Br J Haematol (2007) 2.09
NPP-type ectophosphodiesterases: unity in diversity. Trends Biochem Sci (2005) 2.08
Inhibition of autotaxin by lysophosphatidic acid and sphingosine 1-phosphate. J Biol Chem (2005) 1.95
Autotaxin/lysopholipase D and lysophosphatidic acid regulate murine hemostasis and thrombosis. J Biol Chem (2009) 1.78
Lipid phosphate phosphatases and signaling. J Lipid Res (2008) 1.70
Lysophosphatidic acid (LPA) and its receptors. Curr Opin Pharmacol (2008) 1.70
Carba analogs of cyclic phosphatidic acid are selective inhibitors of autotaxin and cancer cell invasion and metastasis. J Biol Chem (2006) 1.61
Autotaxin (ATX), a potent tumor motogen, augments invasive and metastatic potential of ras-transformed cells. Oncogene (2000) 1.60
Roles for lipid phosphate phosphatases in regulation of cellular signaling. Biochim Biophys Acta (2002) 1.59
The absence of LPA2 attenuates tumor formation in an experimental model of colitis-associated cancer. Gastroenterology (2009) 1.56
LPA1 receptor activation promotes renal interstitial fibrosis. J Am Soc Nephrol (2007) 1.51
Lipid phosphate phosphohydrolase type 1 (LPP1) degrades extracellular lysophosphatidic acid in vivo. Biochem J (2009) 1.38
S32826, a nanomolar inhibitor of autotaxin: discovery, synthesis and applications as a pharmacological tool. J Pharmacol Exp Ther (2008) 1.28
In vitro genetic screen identifies a cooperative role for LPA signaling and c-Myc in cell transformation. Oncogene (2008) 1.17
Virtual screening approaches for the identification of non-lipid autotaxin inhibitors. Bioorg Med Chem (2007) 1.09
Involvement of the lysophosphatidic acid-generating enzyme autotaxin in lymphocyte-endothelial cell interactions. Am J Pathol (2008) 1.08
Anticancer activity of FTY720: phosphorylated FTY720 inhibits autotaxin, a metastasis-enhancing and angiogenic lysophospholipase D. Cancer Lett (2008) 1.07
Rapid clearance of the circulating metastatic factor autotaxin by the scavenger receptors of liver sinusoidal endothelial cells. Cancer Lett (2009) 1.00
alpha- and beta-substituted phosphonate analogs of LPA as autotaxin inhibitors. Bioorg Med Chem (2007) 0.93
The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol (2008) 7.86
The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer (2003) 6.70
Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J (2007) 6.26
The ins and outs of lysophosphatidic acid signaling. Bioessays (2004) 3.62
Chemistry-based functional proteomics reveals novel members of the deubiquitinating enzyme family. Chem Biol (2002) 3.43
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell (2005) 3.41
Vascular endothelial growth factor B controls endothelial fatty acid uptake. Nature (2010) 3.40
Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Mol Cell Biol (2006) 3.24
Bmi1 controls tumor development in an Ink4a/Arf-independent manner in a mouse model for glioma. Cancer Cell (2007) 3.14
Design and use of conditional MHC class I ligands. Nat Med (2006) 3.01
Detecting cAMP-induced Epac activation by fluorescence resonance energy transfer: Epac as a novel cAMP indicator. EMBO Rep (2004) 2.98
Loss of HAUSP-mediated deubiquitination contributes to DNA damage-induced destabilization of Hdmx and Hdm2. Mol Cell (2005) 2.76
Structure of the ubiquitin hydrolase UCH-L3 complexed with a suicide substrate. J Biol Chem (2004) 2.75
piRNA-associated germline nuage formation and spermatogenesis require MitoPLD profusogenic mitochondrial-surface lipid signaling. Dev Cell (2011) 2.73
Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol Cancer Ther (2002) 2.60
Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome. Structure (2006) 2.56
Generation of peptide-MHC class I complexes through UV-mediated ligand exchange. Nat Protoc (2006) 2.47
Rap1b is required for normal platelet function and hemostasis in mice. J Clin Invest (2005) 2.46
Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc Natl Acad Sci U S A (2007) 2.39
Regulation and biological activities of the autotaxin-LPA axis. Prog Lipid Res (2007) 2.39
Biphasic roles for soluble guanylyl cyclase (sGC) in platelet activation. Blood (2011) 2.27
5-Fluoro-2-indolyl des-chlorohalopemide (FIPI), a phospholipase D pharmacological inhibitor that alters cell spreading and inhibits chemotaxis. Mol Pharmacol (2008) 2.24
Zinc-finger protein A20, a regulator of inflammation and cell survival, has de-ubiquitinating activity. Biochem J (2004) 2.23
TRPM7, a novel regulator of actomyosin contractility and cell adhesion. EMBO J (2006) 2.20
Intracellular bacterial growth is controlled by a kinase network around PKB/AKT1. Nature (2007) 2.19
Lysophosphatidic acid is a potential mediator of cholestatic pruritus. Gastroenterology (2010) 2.18
International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid receptor nomenclature. Pharmacol Rev (2010) 2.10
Differential dependence of CD4+CD25+ regulatory and natural killer-like T cells on signals leading to NF-kappaB activation. Proc Natl Acad Sci U S A (2004) 2.09
Expression of the splicing factor gene SFRS10 is reduced in human obesity and contributes to enhanced lipogenesis. Cell Metab (2011) 2.08
Phospholipase D. Biochem Cell Biol (2004) 2.06
Stabilization of the transcription factor Foxp3 by the deubiquitinase USP7 increases Treg-cell-suppressive capacity. Immunity (2013) 2.05
OTU deubiquitinases reveal mechanisms of linkage specificity and enable ubiquitin chain restriction analysis. Cell (2013) 2.05
Disease-associated prion protein oligomers inhibit the 26S proteasome. Mol Cell (2007) 2.01
Inhibition of autotaxin by lysophosphatidic acid and sphingosine 1-phosphate. J Biol Chem (2005) 1.95
Kringle 5 of human plasminogen induces apoptosis of endothelial and tumor cells through surface-expressed glucose-regulated protein 78. Cancer Res (2005) 1.94
Specific and covalent targeting of conjugating and deconjugating enzymes of ubiquitin-like proteins. Mol Cell Biol (2004) 1.86
Chemical synthesis of ubiquitin, ubiquitin-based probes, and diubiquitin. Angew Chem Int Ed Engl (2010) 1.83
Structural basis of substrate discrimination and integrin binding by autotaxin. Nat Struct Mol Biol (2011) 1.81
Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme. BMC Cancer (2009) 1.80
Autotaxin/lysopholipase D and lysophosphatidic acid regulate murine hemostasis and thrombosis. J Biol Chem (2009) 1.78
Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib. Nat Methods (2005) 1.78
Conditional MHC class I ligands and peptide exchange technology for the human MHC gene products HLA-A1, -A3, -A11, and -B7. Proc Natl Acad Sci U S A (2008) 1.77
P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan. Clin Cancer Res (2007) 1.74
Coplanar polychlorinated biphenyls impair glucose homeostasis in lean C57BL/6 mice and mitigate beneficial effects of weight loss on glucose homeostasis in obese mice. Environ Health Perspect (2012) 1.73
Integral membrane lipid phosphatases/phosphotransferases: common structure and diverse functions. Biochem J (2005) 1.67
Validity of bioluminescence measurements for noninvasive in vivo imaging of tumor load in small animals. Biotechniques (2007) 1.66
Autotaxin and LPA receptor signaling in cancer. Cancer Metastasis Rev (2011) 1.61
Podoplanin maintains high endothelial venule integrity by interacting with platelet CLEC-2. Nature (2013) 1.61
Roles for lipid phosphate phosphatases in regulation of cellular signaling. Biochim Biophys Acta (2002) 1.59
The differential modulation of USP activity by internal regulatory domains, interactors and eight ubiquitin chain types. Chem Biol (2011) 1.58
Rac activation by lysophosphatidic acid LPA1 receptors through the guanine nucleotide exchange factor Tiam1. J Biol Chem (2002) 1.57
The lipid phosphatase LPP3 regulates extra-embryonic vasculogenesis and axis patterning. Development (2003) 1.57
Mechanism of USP7/HAUSP activation by its C-terminal ubiquitin-like domain and allosteric regulation by GMP-synthetase. Mol Cell (2011) 1.56
An ankyrin-repeat ubiquitin-binding domain determines TRABID's specificity for atypical ubiquitin chains. Nat Struct Mol Biol (2011) 1.55
CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. Blood (2007) 1.54
A fluorescent broad-spectrum proteasome inhibitor for labeling proteasomes in vitro and in vivo. Chem Biol (2006) 1.54
Cardiac response to pressure overload in 129S1/SvImJ and C57BL/6J mice: temporal- and background-dependent development of concentric left ventricular hypertrophy. Am J Physiol Heart Circ Physiol (2006) 1.52
Plasma lysophosphatidic acid concentration and ovarian cancer. JAMA (2002) 1.51
Long-lasting suppression of hippocampal cell proliferation and impaired cognitive performance by methotrexate in the rat. Behav Brain Res (2007) 1.48
S1P promotes murine progenitor cell egress and mobilization via S1P1-mediated ROS signaling and SDF-1 release. Blood (2012) 1.47
Regulation of phospholipase D1 subcellular cycling through coordination of multiple membrane association motifs. J Cell Biol (2003) 1.47
The deubiquitinating enzyme UCH-L3 regulates the apical membrane recycling of the epithelial sodium channel. J Biol Chem (2007) 1.43
Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. J Clin Invest (2007) 1.41
Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activators of PPARgamma, and inhibitors of autotaxin. J Med Chem (2005) 1.40
Neuropilin-1 in regulation of VEGF-induced activation of p38MAPK and endothelial cell organization. Blood (2008) 1.38
Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice. Mol Cancer Ther (2008) 1.36
Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res (2004) 1.35
Fluorogenic phospholipid substrate to detect lysophospholipase D/autotaxin activity. Org Lett (2006) 1.34
Roles of lysophosphatidic acid in cardiovascular physiology and disease. Biochim Biophys Acta (2008) 1.34
Periostin mediates vascular smooth muscle cell migration through the integrins alphavbeta3 and alphavbeta5 and focal adhesion kinase (FAK) pathway. Atherosclerosis (2009) 1.33
Spider and bacterial sphingomyelinases D target cellular lysophosphatidic acid receptors by hydrolyzing lysophosphatidylcholine. J Biol Chem (2004) 1.33
On terminal alkynes that can react with active-site cysteine nucleophiles in proteases. J Am Chem Soc (2013) 1.32
Increased penetration of paclitaxel into the brain by inhibition of P-Glycoprotein. Clin Cancer Res (2003) 1.32
Inhibition of fatty acid synthase attenuates CD44-associated signaling and reduces metastasis in colorectal cancer. Cancer Res (2012) 1.31
Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin. Nat Commun (2013) 1.31
Modulation of the blood-brain barrier in oncology: therapeutic opportunities for the treatment of brain tumours? Cancer Treat Rev (2004) 1.28
Elevated p53 expression is associated with dysregulation of the ubiquitin-proteasome system in dilated cardiomyopathy. Cardiovasc Res (2008) 1.28
Discovery, biological evaluation, and structure-activity relationship of amidine based sphingosine kinase inhibitors. J Med Chem (2010) 1.28
Physiologically relevant metal cofactor for methionine aminopeptidase-2 is manganese. Biochemistry (2003) 1.28
MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int J Cancer (2005) 1.27
Therapeutic potential of autotaxin/lysophospholipase d inhibitors. Curr Drug Targets (2008) 1.27
Two novel ubiquitin-fold modifier 1 (Ufm1)-specific proteases, UfSP1 and UfSP2. J Biol Chem (2006) 1.26